Treatment of Kaposi's sarcoma.
Von Roenn
J H
JH
Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Fox Chase Cancer Center, USA.
Cianfrocca
M
M
D018943:Anthracyclines / Q000008:administration & dosage / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D000998:Antiviral Agents / Q000627:therapeutic use; D018791:CD4 Lymphocyte Count; D002986:Clinical Trials as Topic; D017679:Cryotherapy; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000150:complications; D015497:HIV-1; D019288:Herpesvirus 8, Human; D006801:Humans; D007372:Interferons / Q000627:therapeutic use; D008081:Liposomes; D010808:Physical Examination; D017410:Practice Guidelines as Topic; D011379:Prognosis; D012142:Respiratory Tract Neoplasms / Q000473:pathology; D012176:Retinoids / Q000008:administration & dosage / Q000627:therapeutic use; D012514:Sarcoma, Kaposi / Q000150:complications / Q000473:pathology / Q000628:therapy*; D012878:Skin Neoplasms / Q000150:complications / Q000473:pathology / Q000628:therapy*; D019562:Viral Load
D018943:Anthracyclines; D000970:Antineoplastic Agents; D000998:Antiviral Agents; D008081:Liposomes; D012176:Retinoids; D007372:Interferons